Company

Ayala Pharmaceuticals, Inc.

Headquarters: Rehovot, Israel

Employees: 34

CEO: Dr. Roni Mamluk Ph.D.

NASDAQ: AYLA

Market Cap

$7.5 Million

USD as of Jan. 1, 2023

Market Cap History

Ayala Pharmaceuticals, Inc. market capitalization over time

Evolution of Ayala Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Ayala Pharmaceuticals, Inc.

Detailed Description

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Ayala Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: AYLA wb_incandescent

Details

Headquarters:

Oppenheimer 4

Rehovot, 7670104

Israel

Phone: 972 8 373 1541